CD274 and non-small cell lung carcinoma: Disease and treatment characteristics of this final population of metastatic NSCLC patients evaluated for irAEs (such as demographics, histological features, metastasis sites, PD-L1 expression, response to ICI treatment and prior and subsequent treatments) are thoroughly described in Table 3.